加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$54.88
+US$0.11 · +0.20%
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
前收盘价
US$54.88
+US$0.11 · +0.20%
盘前
US$54.70
−US$0.18 · -0.33%
10月8日 9:15 ET
盘中时间采用ET。市场数据可能有所延迟。
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
日内区间
当前US$54.88
52周区间
当前US$54.88
盘中时间采用ET。市场数据可能有所延迟。
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
日内区间
当前US$54.88
52周区间
当前US$54.88
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7995万 USD | 3901.1万 USD | 3164.2万 USD | 2125.1万 USD | 2183.2万 USD |
| 销货成本 | 3721万 USD | 1560万 USD | 1058.1万 USD | 693.3万 USD | 262.3万 USD |
| 毛利 | 4274万 USD | 2341.1万 USD | 2106.1万 USD | 1431.8万 USD | 1920.9万 USD |
| 研究与开发 | 776.5万 USD | 325.5万 USD | 332.2万 USD | 399.6万 USD | 623.5万 USD |
| 销售、一般及管理费用 | 3581.9万 USD | 2275.3万 USD | 1893.1万 USD | 1858.2万 USD | 1446.9万 USD |
| 营业费用 | 4266.8万 USD | 2600.8万 USD | 2225.3万 USD | 2257.8万 USD | 2070.4万 USD |
| 利息支出 | 478.1万 USD | 200.5万 USD | 106万 USD | 95.5万 USD | 104.2万 USD |
| 折旧和摊销 | 404.4万 USD | 114.6万 USD | 90.1万 USD | 177.4万 USD | 46.2万 USD |
| 营业利润 | 7.2万 USD | −259.7万 USD | −119.2万 USD | −826万 USD | −149.5万 USD |
| 净利润 | −460.1万 USD | −382.3万 USD | −93.6万 USD | −902.1万 USD | −195.5万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$66.67
上涨空间 21.48%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4212.55万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM3815.53万0.05%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF1655.32万0.02%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO1370.44万0.10%142.49亿 USD0.24%US$355.37-1.43%
State Street SPDR S&P Pharmaceuticals ETFXPH933.14万1.92%4.62亿 USD0.35%US$62.910.00%
Vanguard Russell 2000 ETFVTWO927.51万0.05%180亿 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA775.06万0.04%216.99亿 USD0.03%US$32.61-1.47%
iShares Micro-Cap ETFIWC458.03万0.34%13.33亿 USD0.60%US$183.36-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
